Satellite Bio, a biotech startup, embarks on a challenging enterprise of working on a technology that restores organs by bioengineering tissues. Satellite Bio is ready to finance this particular regenerative therapy with $110 million. The organisation claims that the said technology will work on almost any type of cell. The startup aims to bioengineer tissues that will restore, mend, or replace a less functional organ. The model demonstrates how this approach will be different and workable than the previous experiments conducted for organ function restoration.
Read More from MedCityNews
